Merck says Keytruda injection on par with approved IV version in trial
Adds shares in paragraph 2, background in paragraphs 7-10
Nov 19 (Reuters) -Merck MRK.N said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently approved intravenous formulation of its treatment, likely making it even more accessible and easier to administer.
Shares of Merck were up 1.8% in premarket trading following the news.
The pharmaceutical company was testing the injectable version of the world's biggest-selling drug in a late-stage trial of patients with a type of lung cancer.
The injectable version could potentially protect the drug, which had sales of about $25 billion last year, from competition that is expected when the IV version loses exclusivity later in the decade.
Merck plans to discuss the results with regulators globally as soon as possible, said Marjorie Green, head of oncology, global clinical development at the company's research unit.
Keytruda was injected under the skin in about 2-3 minutes in the trial, compared with the current delivery method in which patients are put on an intravenous drip for about 30 minutes in a health office once every three or six weeks.
Despite the short time of administration, the injectable version was also non-inferior in terms of exposure in the patients' bodies as well as its concentration immediately before the next dose was administered, Merck said.
The injection is a fixed-dose combination of Keytruda with berahyaluronidase alfa, an enzyme that allows large volume of subcutaneous, or under the skin, administration of drugs that are typically given as an IV infusion.
Several pharmaceutical companies are developing injectable versions of their IV drugs using variants of hyaluronidase to offer quick alternatives.
South Korea-based biopharmaceutical company Alteogen 196170.KQ is developing and manufacturing the enzyme used with Keytruda. It is also developing an injectable version of Daiichi Sankyo's 4568.T cancer drug Enhertu.
Alteogen's rival Halozyme HALO.O is also developing injectable versions of various drugs from Roche ROG.S, Johnson & Johnson JNJ.N, Pfizer PFE.N and others.
Reporting by Leroy Leo in Bengaluru; Editing by Anil D'Silva and Krishna Chandra Eluri
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
